American Journal of Infectious Diseases

NEWER DRUGS FOR VISCERAL LEISHMANIASIS: A REVIEW

Krishna Pandey, Dharmendra Singh, Sanjiva Bimal, Vidyanand Rabidas, Krishna Murti, Chadrashekhar Lal and P. Das

DOI : 10.3844/ajidsp.2014.68.70

American Journal of Infectious Diseases

Volume 10, Issue 2

Pages 68-70

Abstract

Visceral Leishmaniasis (VL) is one of the most neglected tropical diseases worldwide. The diagnosis and treatment of this disease is quite complex. Sodium Antimony Gluconate (SAG) which used to be a very effective treatment has now developed resistance and is potentially a cardio-toxic drug. Pentamidine has now been discarded because of adverse effect of diabetes mellitus. Amphotericin-B is an effective drug but can cause nephrotoxicity. Miltefosine is a new oral effective drug which has recently been introduced in the kala-azar elimination program in the Indian subcontinent. Paromomycin is an injectable aminoglycoside which is quite cheap but can cause ototoxicity and nephrotoxicity. Sitamaquine, an oral antimalarial drug is still in phase-II trial stage. Combination Therapy is been tried with good results. Single dose Ambisome (liposomal Amphotericin-B) though costly is a very good alternative.

Copyright

© 2014 Krishna Pandey, Dharmendra Singh, Sanjiva Bimal, Vidyanand Rabidas, Krishna Murti, Chadrashekhar Lal and P. Das. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.